AstraZeneca is a global, innovation and research-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, renal, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries. The innovative portfolio of medicines of AstraZeneca are used by millions of patients worldwide. AstraZeneca IDEA-FAST members bring a variety of scientific expertise along with years of analytical, regulatory, and digital strategy knowledge to the project.
Main tasks in the project
AZ will contribute to WPs 2, 3, 5 and 6 with knowledge and expertise in areas as Digital Technology, Devices, Data Management and Analysis of streaming data and big data sets
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853981. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and PARKINSON’S DISEASE SOCIETY OF THE UNITED KINGDOM LBG.